NCCN 2015 GU Congress Webinar Series: Metastatic RCC: Selecting Optimal First-Line and Subsequent-Lines of Therapy

December 2, 2015

This educational initiative addresses healthcare professionals’ need to be educated on practice-changing developments in the management of advanced genitourinary cancers that have taken center stage in recent years. The expansion of treatment options has improved patient care but has presented numerous clinical challenges.  For example, despite significant improvements in responses and survival with the use of TKIs and mTOR inhibitors as first-line therapy in patients with RCC, progression is universal in these patients. This underscores the need to understand optimal second-line therapy, optimal sequence of therapies, and novel treatment approaches such as immunotherapeutics that are currently in various phases of clinical development.

Metastatic prostate cancer has seen rapid expansion of therapeutic options, and, therefore, clinicians managing these patients are challenged to acquire, comprehend, and integrate the latest clinical evidence and recommendations. Additionally, prostate cancer and its treatments are associated with a diverse array of possible symptoms that can have a large negative impact on men’s quality of life both during and after treatment. Clinicians need to be updated on management strategies for the most common and troubling symptoms, including important novel treatments for patients with bone metastases that can improve bone health and prolong survival.

Although the standard of care for the treatment of advanced bladder cancer has remained mostly unchanged over the last 30 years, clinical trial data continue to provide insight into potential new therapies. The use of bladder-preserving strategies has improved quality of life, and newer agents that include molecularly targeted therapies and immunotherapies may further improve patient outcomes.

Target Audience

This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, urologists, and other healthcare professionals who manage patients with GU cancers.

Learning Objectives

Following this activity, participants should be able to:

  • Explain the molecular biology of renal cell carcinoma
  • Categorize the risks and benefits of the current therapeutic options available for patients with newly diagnosed advanced renal cell carcinoma
  • Select optimal subsequent lines of treatment to improve outcomes of patients with advanced RCC
  • Discuss the scientific rationale used in developing current and emerging therapeutics for advanced RCC
Additional information

This activity is supported by an independent educational grant from Astellas and Medivation, Inc.

Supported by educational grants from Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, and Prometheus Laboratories Inc.

Course summary
Available credit: 
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Course opens: 
Course expires: 
Event starts: 
12/02/2015 - 1:00pm EST
Event ends: 
12/02/2015 - 2:15pm EST

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center

M. Dror Michaelson, MD, PhD
Massachusetts General Hospital Cancer Center


All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.


National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.25 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.


National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge 

National Comprehensive Cancer Network designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-15-136-L01-P

Available Credit

  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing